Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

ILLUMINA, INC.

(ILMN)
  Report
Delayed Quote. Delayed Nasdaq - 10/23 04:00:00 pm
323.55 USD   -0.73%
10/07ILLUMINA, INC. : Report
CO
10/05ILLUMINA, INC. : Report
CO
10/01ILLUMINA, INC. : Report
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina : to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020

share with twitter share with LinkedIn share with facebook
09/28/2020 | 08:02am EDT

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 29, 2020. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the “company” tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with Conference ID 9488740. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about ILLUMINA, INC.
10/07ILLUMINA, INC. : Report
CO
10/05ILLUMINA, INC. : Report
CO
10/01ILLUMINA, INC. : Report
CO
09/28ILLUMINA : to Announce Third Quarter 2020 Financial Results on Thursday, October..
BU
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
DJ
09/23ILLUMINA : to Webcast Upcoming Investor Conference Presentation
BU
09/21Nikola, Illumina fall; Cubic, Rent-A-Center rise
AQ
09/21Nikola, Illumina fall; Cubic, Rent-A-Center rise
AQ
09/21Illumina to buy Jeff Bezos-backed cancer testing firm Grail in £6.23 billion ..
RE
09/21JEFF BEZOS : Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 b..
RE
More news
Financials (USD)
Sales 2020 3 095 M - -
Net income 2020 550 M - -
Net cash 2020 2 068 M - -
P/E ratio 2020 87,9x
Yield 2020 -
Capitalization 47 355 M 47 355 M -
EV / Sales 2020 14,6x
EV / Sales 2021 11,8x
Nbr of Employees 7 700
Free-Float 75,1%
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 297,25 $
Last Close Price 323,55 $
Spread / Highest target 17,4%
Spread / Average Target -8,13%
Spread / Lowest Target -32,0%
EPS Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Robert P. Ragusa Senior Vice President-Global Quality & Operations
Sam A. Samad Chief Financial Officer & Senior Vice President
Phillip G. Febbo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.-2.47%47 355
THERMO FISHER SCIENTIFIC47.80%189 950
DANAHER CORPORATION51.59%165 276
INTUITIVE SURGICAL, INC.24.42%86 460
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.95.16%64 541
BOSTON SCIENTIFIC CORPORATION-17.80%53 178